MAIA Biotechnology, Inc. is making significant strides in developing a potential breakthrough therapeutic for third-line non-small cell lung cancer (NSCLC). With unmatched efficacy data and FDA Fast Track designation for ateganosine, the company is on track for early commercial approval. This telomere-targeting anticancer agent has the potential to tap into the estimated $50+ billion global immunotherapy market. Key milestones for 2026 include Phase 3 trial results, completion of Phase 2 study, regulatory interactions with the FDA, and the start of Phase 1 trials for second-generation molecules. Ateganosine shows promise as a targeted therapy for NSCLC patients with telomerase-positive cancer cells. For more information, visit www.maiabiotech.com.

Read more at GlobeNewswire: MAIA Biotechnology Advances Ateganosine Cancer Treatment